STOCK TITAN

Inari Medical Inc - NARI STOCK NEWS

Welcome to our dedicated news page for Inari Medical (Ticker: NARI), a resource for investors and traders seeking the latest updates and insights on Inari Medical.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Inari Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Inari Medical's position in the market.

Rhea-AI Summary
Inari Medical, Inc. (NASDAQ: NARI) will announce its first quarter 2024 financial results on April 30, 2024. The company aims to transform the lives of patients with venous and other diseases. A conference call and webcast will be held to discuss the financial results and recent highlights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Inari Medical, Inc. (NARI) releases its 2023 Ethos and Sustainability Report, showcasing its commitment to ESG initiatives. The report emphasizes the company's dedication to treating patients with venous and other diseases while prioritizing environmental and social responsibilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.78%
Tags
none
-
Rhea-AI Summary
Inari Medical, Inc. (NASDAQ: NARI) appoints Tim Benner as Senior VP of U.S. Sales and Dr. Andrew Niekamp as VP of Medical Affairs. Benner brings 16 years of experience in healthcare technologies, while Dr. Niekamp is a skilled clinician with a focus on venous thromboembolism.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.39%
Tags
management
Rhea-AI Summary
Inari Medical, Inc. (NASDAQ: NARI) announces positive two-year interim results from the CLOUT registry, showcasing excellent safety, effectiveness, and long-term outcomes of the ClotTriever system in treating deep vein thrombosis patients. The data presented at the American Venous Forum meeting reveals significantly lower rates of Post Thrombotic Syndrome compared to historical trials, emphasizing the sustained benefits of the treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.84%
Tags
none
-
Rhea-AI Summary
Inari Medical, Inc. (NASDAQ: NARI) reported strong financial results for Q4 and full year 2023, with revenue reaching $132.1 million in Q4, a 22.6% increase over the previous year. The company closed the LimFlow acquisition and completed enrollment in the PEERLESS trial. Inari expects revenue of $580-595 million for 2024, aiming for sustained operating profitability in the first half of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.84%
Tags
-
Rhea-AI Summary
Inari Medical, Inc. (NASDAQ: NARI) to announce fourth quarter and full year 2023 financial results on February 28, 2024. Conference call and webcast scheduled to discuss financial results and recent highlights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.36%
Tags
Rhea-AI Summary
Inari Medical, Inc. (NARI) reported preliminary unaudited fourth quarter revenue of at least $132.0 million, up 22% year-over-year and full year revenue of at least $493.5 million, up 29% over 2022. The company also established its 2024 financial guidance, expecting revenue of $580 million to $595 million and reaching sustained operating profitability in the first half of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.08%
Tags
none
-
Rhea-AI Summary
Okami Medical Inc. (Ticker: OMI) appoints Rhonda Robb as President and CEO, bringing over 25 years of leadership and commercial experience in the medical device industry. The company is preparing to commercialize the LOBO Vascular Occlusion System, a next-generation technology addressing peripheral vascular conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
management
-
Rhea-AI Summary
Inari Medical, Inc. (NASDAQ: NARI) to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.97%
Tags
conferences
Rhea-AI Summary
Inari Medical, Inc. (NARI) announced the first patient enrollment in the PEERLESS II study, a global clinical trial comparing the outcomes of intermediate-risk acute pulmonary embolism patients treated with the FlowTriever® System against traditional anticoagulation therapy. The study aims to generate evidence to influence PE treatment guidelines worldwide and establish FlowTriever as the optimal therapy for intermediate-risk PE patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
none
Inari Medical Inc

Nasdaq:NARI

NARI Rankings

NARI Stock Data

2.36B
52.39M
9.55%
94.14%
6.89%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
Irvine

About NARI

inari medical is a medical device company pioneering devices for the interventional treatment of vascular thrombi and emboli.